In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Women Mean Business (WMB) Businesswoman Award 2024
Following her receipt of the WMB Businesswoman Award 2024, Rose Kidd, President, Operations Delivery is interviewed by Women Mean Business on her role, the opportunities for the life sciences industry and her views on how we can support more women to progress STEM careers.
-
Striking the right balance between transparency and privacy in clinical trial data sharing
In this article, our experts explore how to strike the right balance between adequately anonymising clinical trial data to protect participant privacy and company assets, while still preserving its value for research purposes (see page 16).
-
How AI can manage the risks and costs of postmarketing requirements
Postmarketing requirements (PMRs) for drug development are commonly required to gather data on a product’s longer-term safety, efficacy and optimal use. Carefully applied AI and machine learning offers the potential for better management of PMRs.
-
Strategies for commercialising oncology treatments for young adults
This article explores the imperatives and strategies for commercialising oncology treatments targeting young adults, highlighting the need for innovative regulatory and commercial strategies to ensure successful market entry and improved patient outcomes.
-
Obesity trial surge puts the focus back on decentralisation
Explore the evolving obesity clinical trials landscape and the role of decentralisation and new technologies in this recent CTA article.
-
The Pivotal Role of Patient Advocacy Organisations in Driving Rare Disease Therapeutic Development
ICON’s Dr Neena Nizar and Dr Jana Benesh discuss the ways effective engagement with PAOs is shaping rare disease research and contributing to better therapeutic outcomes. Read the article in IPI for insights into patient engagement in preclinical, clinical and post-approval phases of development.
-
Therapeutic Focus - Pushing Boundaries in Idiopathic Pulmonary Fibrosis Clinical Research
With more than 170 early stage IPF clinical programs, IPF is one of the most dynamic rare diseases spaces for development.
-
Blending Models for Better Sourcing Solutions
There is a growing trend among large and midsize pharma in turning toward more strategic partnerships to help them navigate the increasing complexity of the development landscape and the compounding macroeconomic constraints. Read our Whitepaper: Embracing a blended operating model for more details.
-
ICON’s advances on the perpetual path of innovation in laboratory solutions
Innovative laboratory solutions have the potential to optimise clinical research processes, create more efficient operations and improve sustainability to support wider organisational objectives. In this article published by R&D World, ICON outlines some of the new initiatives that are in progress to ensure the continued delivery of high quality results that meet sponsors’ needs – today and tomorrow.
-
Survey shows varied views on impact of new cancer drugs
This article published in The Pharma Letter highlights findings from an ICON survey has found that despite the increasing investment in emerging oncology-related therapeutics, developers have varied views on the impact of new cancer drugs for patients.
